<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118525</article-id><article-id pub-id-type="publisher-id">ACM-44700</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_18702147.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  视网膜静脉阻塞性黄斑水肿的治疗进展
  Progress in the Treatment of Retinal Vein Obstructive Macular Edema
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>莎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>霍</surname><given-names>昭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，眼科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3592</fpage><lpage>3598</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  视网膜静脉阻塞(RVO)是一种常见的血管性疾病，黄斑水肿(ME)是其常见并发症，也是引起视力下降的主要原因。随着对RVO发病机制的进一步了解和研究，黄斑部格栅样激光光凝、玻璃体腔注射激素或抗血管内皮生长因子(VEGF)药物、玻璃体切割术、视神经切开术等治疗方法成为RVO-ME治疗的主要研究方向。现就RVO-ME的治疗进展进行综述。
   Retinal vein occlusion (RVO) is a common vascular disease, and macular edema (ME) is a common complication and the main cause of vision loss. With the further understanding and research of the pathogenesis of RVO, macular grille laser photocoagulation, intravitreal injection of hormones or anti-vascular endothelial growth factor (VEGF) drugs, vitrectomy, optic neurotomy and other treatment methods are the main research directions of RVO-ME treatment. This article reviews the treatment progress of RVO-ME.
 
</p></abstract><kwd-group><kwd>视网膜静脉阻塞，黄斑水肿，治疗，综述, Retinal Vein Occlusion</kwd><kwd> Macular Edema</kwd><kwd> Treatment</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>视网膜静脉阻塞(RVO)是一种常见的血管性疾病，黄斑水肿(ME)是其常见并发症，也是引起视力下降的主要原因。随着对RVO发病机制的进一步了解和研究，黄斑部格栅样激光光凝、玻璃体腔注射激素或抗血管内皮生长因子(VEGF)药物、玻璃体切割术、视神经切开术等治疗方法成为RVO-ME治疗的主要研究方向。现就RVO-ME的治疗进展进行综述。</p></sec><sec id="s2"><title>关键词</title><p>视网膜静脉阻塞，黄斑水肿，治疗，综述</p></sec><sec id="s3"><title>Progress in the Treatment of Retinal Vein Obstructive Macular Edema<sup> </sup></title><p>Sha Yan, Zhao Huo, Fei Wang</p><p>Department of Ophthalmology, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/42-1572476x4_hanspub.png?20210823171715687" /></p><p>Received: Jul. 18<sup>th</sup>, 2021; accepted: Aug. 16<sup>th</sup>, 2021; published: Aug. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/42-1572476x5_hanspub.png?20210823171715687" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Retinal vein occlusion (RVO) is a common vascular disease, and macular edema (ME) is a common complication and the main cause of vision loss. With the further understanding and research of the pathogenesis of RVO, macular grille laser photocoagulation, intravitreal injection of hormones or anti-vascular endothelial growth factor (VEGF) drugs, vitrectomy, optic neurotomy and other treatment methods are the main research directions of RVO-ME treatment. This article reviews the treatment progress of RVO-ME.</p><p>Keywords:Retinal Vein Occlusion, Macular Edema, Treatment, Review</p><disp-formula id="hanspub.44700-formula11"><graphic xlink:href="//html.hanspub.org/file/42-1572476x6_hanspub.png?20210823171715687"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/42-1572476x7_hanspub.png?20210823171715687" /> <img src="//html.hanspub.org/file/42-1572476x8_hanspub.png?20210823171715687" /></p></sec><sec id="s5"><title>1. 引言</title><p>视网膜静脉阻塞(retina vein occlusion, RVO)总体患病率约为0.52% [<xref ref-type="bibr" rid="hanspub.44700-ref1">1</xref>]，是仅次于糖尿病视网膜病变的第二大常见眼部血管病 [<xref ref-type="bibr" rid="hanspub.44700-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref5">5</xref>]。根据缺血部位不同，又分为视网膜中央静脉阻塞(central retina vein 0cclusion, CRVO)和视网膜分值静脉阻塞(branch retinal vein occlusion, BRVO)，其继发的黄斑水肿(macular edema, ME)及视网膜大面积缺血是导致RVO患者视力下降的主要原因 [<xref ref-type="bibr" rid="hanspub.44700-ref6">6</xref>]，长期存在的ME可造成永久性的视网膜结构损伤，引起中心视力的不断下降，最终导致失明。RVO-ME是由于疾病导致了血管内皮及外层血视网膜屏障的破坏，黄斑区细胞内和细胞外液体生成、引流平衡被打破，从而造成液体积聚，导致ME [<xref ref-type="bibr" rid="hanspub.44700-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref9">9</xref>]。其发病机制非常复杂，有很多假说和通路可能参与其中，静脉阻塞导致了局部或弥漫的视网膜缺血缺氧损伤 [<xref ref-type="bibr" rid="hanspub.44700-ref10">10</xref>]。视网膜组织在缺血、氧化和代谢应激压力下产生大量炎症介质和细胞因子，升高的炎症因子导致内皮细胞功能障碍、细胞损伤/凋亡，血–视网膜内屏障破坏，白细胞、红细胞和血浆逸出、渗漏，促进视网膜炎症反应加剧，损伤胶质细胞和神经细胞，引起结构和功能上的改变，导致黄斑中央凹引流功能障碍，最终导致黄斑水肿，进而影响患者视功能 [<xref ref-type="bibr" rid="hanspub.44700-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref13">13</xref>]。众所周知，黄斑区的精确视觉是由其特殊的解剖学特征决定的，包括高密度的视锥细胞、视轴的无血管化和视锥细胞及Muller细胞的离心移位。黄斑水肿，将会破坏这种解剖结构，导致光感受器的损伤、视网膜内层神经元的损伤以及ME本身导致光信号的传导障碍，最终导致视力下降，甚至丧失。对于RVO的治疗，主要以减轻ME、预防新生血管性并发症为主。主要包括黄斑部格栅样激光光凝、玻璃体腔注射激素或抗血管内皮生长因子(vascular endothelial growth factor, VEGF)药物，还包括玻璃体切割术、视神经切开术等手术治疗方法，随着对RVO-ME发病机制的逐步认识，治疗方法也在进一步完善。本文将对RVO-ME的治疗进行综述。</p></sec><sec id="s6"><title>2. 激光光凝治疗</title><p>既往有研究发现，BRVO患者视网膜血流灌注情况与视力恢复密切相关 [<xref ref-type="bibr" rid="hanspub.44700-ref14">14</xref>]，早期视网膜浅层血流灌注情况明显改善的患者在治疗后可获得远期视力提高 [<xref ref-type="bibr" rid="hanspub.44700-ref15">15</xref>]。激光光凝术，主要为通过破坏特别是光感受器细胞和视网膜色素上皮层细胞等视网膜外层细胞，使更多的营养和氧供给到视网膜内层 [<xref ref-type="bibr" rid="hanspub.44700-ref16">16</xref>]，增加视网膜浅层血流灌注，从而促进水肿和出血吸收。同时激光有利于脉络膜氧份向视网膜内层通透和视网膜水肿的消散，从而改善视网膜内层的血液供应，促进视网膜组织修复和功能改善 [<xref ref-type="bibr" rid="hanspub.44700-ref17">17</xref>]。黄斑格栅样光凝治疗ME的理论基础源自于20世纪80年代后期，美国早期治疗糖尿病性视网膜病变研究小组(early treatment diabetic retinopathy study group, ETDRSG)提出格栅样光凝治疗ME，可降低持续性黄斑水肿的发生率 [<xref ref-type="bibr" rid="hanspub.44700-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.44700-ref19">19</xref>]。郑波 [<xref ref-type="bibr" rid="hanspub.44700-ref20">20</xref>] 等研究发现，合理的视网膜激光治疗及黄斑格栅样光凝，治疗效果肯定。研究纳入137眼行黄斑区格栅样光凝并行不同程度视网膜光凝的患眼，术后1 mo视力提高眼占36.5%，显著提高者占50.4%；术后3 mo，视力提高眼40.2%，显著高者占50.4%。只要范围够广，有效光凝点量够，均可控制黄斑水肿。选择光凝的时机也非常重要，对黄斑周边早期出现弥漫性水肿进行早期的预防性治疗，效果更佳，但必须对患者进行细致讲解，因为这一部分患者当时往往尚有比较好的视力，治疗后短期内有视力下降的现象存在。陈少军 [<xref ref-type="bibr" rid="hanspub.44700-ref21">21</xref>] 等研究发现，玻璃体腔注射糖皮质激素(曲安奈德4 mg)与黄斑格栅样光凝均可治疗RVO-ME，在中央视网膜厚度 &lt; 500 μm的治疗效果相当，但对于中央视网膜厚度 &gt; 500 μm的黄斑水肿，提出以上两者的联合治疗，联合治疗的时机应在曲安奈德注射后1 wk~1 mo内；若需重复给药，间隔时间最好不小于6 mo。此外，岳建忠 [<xref ref-type="bibr" rid="hanspub.44700-ref22">22</xref>] 等研究发现，玻璃体腔注射雷珠单抗联合激光光凝治疗不仅能有效治疗ＲVO-ME患者，而且还不增加眼压及并发症发生，具有较高的临床疗效，且联合治疗效果明显优于单纯激光治疗。由此可见，黄斑格栅样光凝可作为玻璃体腔注射抗VEGF的补充治疗方法。</p></sec><sec id="s7"><title>3. 激素治疗</title><p>炎症是RVO-ME的重要因素，2019EURETINA (欧洲视网膜专家学会)指出，针对RVO-ME，抗炎治疗非常必要。激素能够下调血管内皮生长因子、使炎症血管的渗透性降低，还可以减轻对血–视网膜屏障的破坏，进而达到治疗ME的目的。</p><sec id="s7_1"><title>3.1. 曲安奈德</title><p>曲安奈德为一种人工合成的长效糖皮质激素。姜燕荣等 [<xref ref-type="bibr" rid="hanspub.44700-ref23">23</xref>] 对RVO-ME患者采用40 g∙L<sup>−1</sup>曲安奈德玻璃体腔注射进行治疗，并对其疗效进行观察，在术后的第1、3、7 d，第2、4、8、12、24周和1年进行随访。随访结束时，CRVO24眼，BRVO15眼中最终随访视力提高者28眼，比术前降低者5眼，不变者6眼。OCT形态恢复正常者15眼，改善者21眼，无改善者3眼。12眼术后出现一过性眼压升高。最后得出结论，玻璃体腔注射TA是一种安全有效的治疗RVO-ME的方法。苏晶等研究评估了1 mg、2 mg和4 mg三种剂量曲安奈德玻璃体腔注射治疗RVO-ME的安全性和有效性，指出治疗后6 mo时，1 mg组疗效基本消失，4 mg组疗效略优于2 mg组，但差异无统计学意义，且2 mg组对于眼压和晶状体的副作用更小，安全性更好。所以认为2 mg曲安奈德是治疗RVO-ME的一个合适的剂量。马艳波等 [<xref ref-type="bibr" rid="hanspub.44700-ref24">24</xref>] 将曲安奈德四种给药方式对RVO-ME的治疗作用进行对比研究后发现，玻璃体腔注射组、后Tenon囊下注射组、球后注射组及结膜下注射组四种给药方式的疗效及安全性无明显差别，但玻璃体腔注射风险较大，所以在治疗时应尽量选择简单易行的给药方式。</p></sec><sec id="s7_2"><title>3.2. 地塞米松玻璃体内植入剂</title><p>地塞米松玻璃体内植入剂(Ozurdex<sup>Ⓡ</sup>; Allergan, Inc., Irvine, CA, USA)在华获CFDA (国家食品药品监督管理总局)批准治疗RVO-ME。2019年11月28日傲迪适成功纳入国家医保目录。傲迪适创新缓释科技，作用于多种细胞发挥全面抗炎作用，1次注射，最长持续6个月，针对RVO-ME全面长效抗炎，降低黄斑水肿，快速改善视力，显著减少注射次数，降低患者治疗费用。Haller等 [<xref ref-type="bibr" rid="hanspub.44700-ref25">25</xref>] 对大型临床随机对照试验GENEVA的研究结果进行了报道，并对其治疗RVO-ME的安全性与有效性进行了评估。研究共计纳入1256名患者，并按1:1:1的比例随机分为假注射组、0.35 mg组和0.7 mg组。0.7 mg组的视力和视网膜厚度改善峰值均发生在治疗后60 d，且这些改善优于假注射组，此后视力开始减退。在6个月后重复注射0.7 mg，6个月后可产生类似结果。假注射组在6个月后给予Ozurdex<sup>Ⓡ</sup>治疗，其视力和视网膜厚度均有所改善，但改善效果比基线时就给予治疗的效果差。Kuppermann等 [<xref ref-type="bibr" rid="hanspub.44700-ref26">26</xref>] 研究显示，Ozurdex<sup>Ⓡ</sup>治疗后第7天就能改善视力。黎晓新等 [<xref ref-type="bibr" rid="hanspub.44700-ref27">27</xref>] 进行了为期6个月的随机、双盲、假注射对照、多中心、3期临床研究，来评估Ozurdex<sup>Ⓡ</sup>治疗中国患者RVO-ME的安全性和有效性，最终得出结论：Ozurdex<sup>Ⓡ</sup>治疗中国患者RVO-ME具有良好的安全性和显著的临床疗效；单次植入Ozurdex<sup>Ⓡ</sup>较假注射可获得持续3~4个月的视力和解剖结构改善。谷潇雅等 [<xref ref-type="bibr" rid="hanspub.44700-ref28">28</xref>] 研究发现，Ozurdex<sup>Ⓡ</sup>对比雷珠单抗治疗RVO-ME，减少了注药次数，但其眼压升高比例明显增高。联合用药也是一种治疗新思路。Moon等研究发现，先注射贝伐单抗，再注射Ozurdex<sup>Ⓡ</sup>，其效果要优于单纯注射贝伐单抗。其具体给药时间间隔以及联合用药的并发症还需要我们进一步探索。</p></sec></sec><sec id="s8"><title>4. 抗VEGF药物治疗</title><p>血管内皮生长因子(VEGF)又被称为血管通透因子。有研究表示，静脉阻塞导致血流不畅，使视网膜处于缺血、缺氧环境，眼内液中受到刺激的VEGF浓度会明显的上调，血–视网膜屏障也会因此而受到破坏，血管内皮细胞受到刺激后，有丝分裂被激活、形成血管生成等一系列信号通路，诱导视网膜新生血管(RNV)生成，RNV通透性高，大量血管内液体渗漏，积聚在视网膜的外丛状层，表现为ME [<xref ref-type="bibr" rid="hanspub.44700-ref29">29</xref>]。Noma等 [<xref ref-type="bibr" rid="hanspub.44700-ref30">30</xref>] 人研究证实，RVO患者玻璃体腔内以及房水中VEGF和VEGF受体浓度的增加与(ME)的严重程度呈正相关，这也为抗VEGF治疗提供了理论依据。目前应用抗VEGF药物有单克隆抗体类药物(如雷珠单抗)和融合蛋白类药物(如阿柏西普等)，研究表明，几种抗VEGF药均能显著提高患者视力，减轻黄斑水肿。</p><sec id="s8_1"><title>4.1. 雷珠单抗</title><p>雷珠单抗是人源化重组抗VEGF单克隆抗体片断Fab部位，对VEGF的所有亚型均有较强的亲和力，通过和VEGF的所有亚型结合，降低血管渗透性，消退黄斑水肿 [<xref ref-type="bibr" rid="hanspub.44700-ref31">31</xref>]。万珊珊等 [<xref ref-type="bibr" rid="hanspub.44700-ref32">32</xref>] 对雷珠单抗治疗RVO-ME的效果及安全性做了Mate分析，共纳入1674只患眼，试验组采用0.5 mg雷珠单抗玻璃体腔内注射，对照组用安慰剂玻璃体腔内注射治疗，具体注射部位及方式不限。结果表示，0.5 mg雷珠单抗组较安慰剂组治疗RVO-ME，能更有效地提高视力，减轻ME，但也会增加白内障等并发症的发生率。李路明等 [<xref ref-type="bibr" rid="hanspub.44700-ref33">33</xref>] 研究比较了玻璃体腔注射雷珠单抗与曲安奈德治疗RVO-ME的疗效。研究共纳入100只患眼，研究组40例患者采取玻璃体内注射雷珠单抗治疗，对照组40例患者采取玻璃体内注射曲安奈德治疗，结果显示，研究组患者治疗总有效率为95%、不良反应发生率为7.5%，均明显优于对照组患者75%、25% (P &lt; 0.05)；治疗后研究组患者视力(1.82 &#177; 0.30)、中心凹厚度(252.20 &#177; 88.50) μm、眼压(15.60 &#177; 3.05) mmHg指标水平改善情况明显优于对照组(P &lt; 0.05)。因此玻璃体内注射雷珠单抗对RVO-ME治疗效果良好，可改善患者视力、中心凹厚度，且治疗的安全性高。但雷珠单抗半衰期较短，ME易复发，需要多次重复注射治疗，这也增加了治疗的风险以及患者的经济压力。</p></sec><sec id="s8_2"><title>4.2. 贝伐单抗</title><p>贝伐单抗是一种人工合成的重组人源化鼠IgG型单克隆抗体，非选择性结合VEGF-A所有亚型，阻断后者与VEGFR-2结合 [<xref ref-type="bibr" rid="hanspub.44700-ref34">34</xref>]。Epstein等 [<xref ref-type="bibr" rid="hanspub.44700-ref35">35</xref>] 研究将60例CRVO患者纳入研究，分为治疗组与假注射组，随访时间为1年。6、12、18、24周治疗组BCVA分别提高7.5、11.4、13.9、14.1个字母，假注射组则分别降低0.3、3.9、3.2、2.0个字母。12个月末，两组BCVA平均提高16.0、4.6个字母。中心视网膜厚度降幅差异无统计学意义。可见，贝伐单抗可显著提高CRVO患者视力，并减轻ME；虽不能完全改善ME，却能提高视力。但贝伐单抗治疗RVO-ME在我国属于超适应证使用，对于患者来说，经济负担较重。</p></sec><sec id="s8_3"><title>4.3. 阿柏西普</title><p>阿柏西普是一种重组融合蛋白，由人VEGF受体1和2的胞外区与人体免疫球蛋白G1的可结晶片段融合而成 [<xref ref-type="bibr" rid="hanspub.44700-ref36">36</xref>]。吴冠男等 [<xref ref-type="bibr" rid="hanspub.44700-ref37">37</xref>] 研究纳入30例患眼，给予玻璃体腔注射40 mg/ml阿柏西普0.05 ml (IVA)治疗，治疗方案为首次注射后按需注射，分别于治疗后1、3、6个月收集相关数据，随访时间6个月，结果表示，与基线时比较，治疗后6个月患眼视力明显提高，黄斑中心凹厚度降低，阿柏西普可有效治疗RVO-ME。Scott等 [<xref ref-type="bibr" rid="hanspub.44700-ref38">38</xref>] 研究表明，IVA治疗RVO效果明显，可显著提高患眼视力，改善ME，且在观察期2年内疗效维持良好。Casselholm de Salles等 [<xref ref-type="bibr" rid="hanspub.44700-ref39">39</xref>] 研究表明，经阿柏西普与雷珠单抗治疗的RVO-ME患眼18个月内最佳矫正视力和黄斑中心凹厚度改善水平无明显差异，然后者(14.4次)比前者(10.9次)注射次数更频繁。</p></sec><sec id="s8_4"><title>4.4. 康柏西普</title><p>康柏西普是中国自主研发的一种新型可溶性全人源重组融合蛋白，受体1的2号位点和受体2的3、4号位点，融合人IgG1的Fc片段，引入结构域4可以改善三维结构，提高二聚体形成效率，从而提高对VEGF的结合能力，延长药物半衰期 [<xref ref-type="bibr" rid="hanspub.44700-ref40">40</xref>]。郭超等 [<xref ref-type="bibr" rid="hanspub.44700-ref41">41</xref>] 对42例RVO-ME患者行玻璃体腔注射康柏西普治疗，治疗方案为1 + PRN，结果显示，玻璃体腔注射康柏西普治疗RVO-ME，可有效改善黄斑水肿，提高患者视力。赵宏锟等 [<xref ref-type="bibr" rid="hanspub.44700-ref42">42</xref>] 为探索康柏西普不同给药方案治疗BRVO-ME的疗效，对40例BRVO-ME患者随机分配，分别给予1 + PRN和3 + PRN方案治疗，结果显示，康柏西普1 + PRN和3 + PRN方案治疗BRVO-ME是有效的，且在短期内可以取得类似的疗效。康柏西普半衰期较长，有望在减少注射次数的同时获得良好疗效，来减少注射相关不良反应的风险，并降低治疗费用。但康柏西普现缺乏大型的前瞻性随机对照研究，故有必要进一步评估该药的有效性和安全性。</p></sec></sec><sec id="s9"><title>5. 手术治疗</title><p>ME经过玻璃体腔注药治疗后仍反复发作是其治疗难点，这不仅增加了治疗风险，也增加了患者的治疗费用。从1992年Lewis首次采用玻璃体切割(PPV)治疗ME，取得了较好的疗效后，很多学者开始对手术治疗ME进行研究。PPV可清除玻璃体内炎性因子，通过增加玻璃体内含氧液体的循环，可改善ME。Nishida等 [<xref ref-type="bibr" rid="hanspub.44700-ref43">43</xref>] 研究表示，PPV治疗BRVO-ME，可有效改善患者的视力和黄斑水肿，且仅需较少的额外治疗，疗效可持续5a以上。张燕等 [<xref ref-type="bibr" rid="hanspub.44700-ref44">44</xref>] 研究表示，玻璃体切割联合内界膜剥离可显著改善RVO继发的黄斑水肿，但术后视力提高不明显。玻璃体切割术可出现视网膜脱离、眼底出血、视野缺损等并发症，因此其有效性及安全性仍需进一步观察。邵毅等 [<xref ref-type="bibr" rid="hanspub.44700-ref45">45</xref>] 通过2019年视网膜专家协会指南解读指出，放射状视神经切开术(RON)在治疗CRVO方面有效证据较少，由于玻璃体内有效药物制剂的出现，RON基本已经被淘汰。</p></sec><sec id="s10"><title>6. 结语</title><p>以上所述为目前RVO-ME的常用治疗方法，多项研究表示，抗VEGF药物疗效良好，已成为RVO-ME的一线治疗方案。但抗VEGF药物价格昂贵，且对于反复复发者需要多次玻璃体腔注射，增加了眼内炎等治疗风险，也在经济和精神方面对患者带来巨大压力。皮质类固醇、激光治疗虽可带来部分并发症，但可作为二线治疗方法。对于RVO继发视网膜牵拉性疾病时，可优先考虑PPV。我们还需要进一步研究，优化RVO-ME的治疗方案。</p></sec><sec id="s11"><title>文章引用</title><p>闫 莎,霍 昭,王 飞. 视网膜静脉阻塞性黄斑水肿的治疗进展Progress in the Treatment of Retinal Vein Obstructive Macular Edema[J]. 临床医学进展, 2021, 11(08): 3592-3598. https://doi.org/10.12677/ACM.2021.118525</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44700-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Paulus, Y.M., Shuai, Y., et al. (2017) New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Etinal Vein Occlusion. Journal of Ophthalmology, 2017, Article ID: 4936924. 
&lt;br&gt;https://doi.org/10.1155/2017/4936924</mixed-citation></ref><ref id="hanspub.44700-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">McIntosh, R.L., Rogers, S.L., Lim, L., et al. (2010) History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology, 117, 1113-1123.</mixed-citation></ref><ref id="hanspub.44700-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Awdeh, R.M., Elsing, S.H., Deramo, V.A., et al. (2010) Vision-Related Quality of Life in Persons with Unilateral Branch Retinal Vein Occlusion Using the 25-Item National Eye Institute Visual Function Questionnaire. British Journal of Ophthalmology, 94, 319-323. &lt;br&gt;https://doi.org/10.1136/bjo.2007.135913</mixed-citation></ref><ref id="hanspub.44700-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Deramo, V.A., Cox, T.A., Syed, A.B., et al. (2003) Vision-Related Quality of Life in People with Central Retinal Vein Occlusion Using the 25-Item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 121, 1297-1302. &lt;br&gt;https://doi.org/10.1001/archopht.121.9.1297</mixed-citation></ref><ref id="hanspub.44700-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Coscas, G., Loewenstein, A., Augustin, A., et al. (2011) Management of Retinal Vein Occlusion-Consensus Document. Ophthalmologica, 226, 4-28. &lt;br&gt;https://doi.org/10.1159/000327391</mixed-citation></ref><ref id="hanspub.44700-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rouvas, A., Petrou, P., Ntouraki, A., Douvali, M., Ladas, I. and Vergados, I. (2010) Intravitreal Ranibizumab (Lucentis) for Branch Retinal Vein Occlusion-Induced Macular Edema. Retina, 30, 893-902.</mixed-citation></ref><ref id="hanspub.44700-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yao, H., Wang, T., Deng, J., et al. (2014) The Development of Blood-Retinal Barrier during the Interaction of Astrocytes with Vascular Wall Cells. Neural Regeneration Research, 9, 1047-1054.</mixed-citation></ref><ref id="hanspub.44700-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Díaz-Cornguez, M., Ramos, C. and Antonetti, D.A. (2017) The Inner Blood-Retinal Barrier: Cellular Basis and Development. Vision Research, 139, 123-137.</mixed-citation></ref><ref id="hanspub.44700-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Klaassen, I., Van Noorden, C.J.F., Schlingemann, RO. (2013) Molecular Basis of the Inner Blood-Retinal Barrier and Its Breakdown in Diabetic Macular Edema and Other Pathological Conditions. Progress in Retinal and Eye Research, 34, 19-48. &lt;br&gt;https://doi.org/10.1016/j.preteyeres.2013.02.001</mixed-citation></ref><ref id="hanspub.44700-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cunha-Vaz, J. (2017) The Blood-Retinal Barrier in the Management of Retinal Disease: Euretina Award Lecture. Ophthalmologica, 237, 1-10. &lt;br&gt;https://doi.org/10.1159/000455809</mixed-citation></ref><ref id="hanspub.44700-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gallina, D., Zelinka, C.P., Cebulla, C.M., et al. (2015) Activation of Glucocorticoid Receptors in Müller Glia is Protective to Retinal Neurons and Suppresses Microglial Reactivity. Experimental Neurology, 273, 114-125. 
&lt;br&gt;https://doi.org/10.1016/j.expneurol.2015.08.007</mixed-citation></ref><ref id="hanspub.44700-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Qi, Y., Zhao, M., Bai, Y., et al. (2014) Retinal Ischemia/Reperfusion Injury Is Mediated by Toll Like Receptor 4 Activation of NLRP3 Inflammasomes. Investigative Ophthalmology &amp; Visual Science, 55, 5466-5475.  
&lt;br&gt;https://doi.org/10.1167/iovs.14-14380</mixed-citation></ref><ref id="hanspub.44700-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kirkley, K.S., Popichak, K.A., Afzali, M.F., et al. (2017) Microglia Amplify Inflammatory Activation of Astrocytes in Manganese Neurotoxicity. Journal of Neuroinflammation, 14, 99. &lt;br&gt;https://doi.org/10.1186/s12974-017-0871-0</mixed-citation></ref><ref id="hanspub.44700-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wakabayashi, T., Sato, T., Hara-Ueno, C., Fukushima, Y., Sayanagi, K., Shiraki, N., et al. (2017) Retinal Microvasculature and Visual Acuity in Eyes with Branch Retinal Vein Occlusion: Imaging Analysis by Optical Coherence Tomography Angiography. Investigative Ophthalmology &amp; Visual Science, 58, 2087-2094.  
&lt;br&gt;https://doi.org/10.1167/iovs.16-21208</mixed-citation></ref><ref id="hanspub.44700-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">夏洋, 周吉林, 黄永健, 邹茜, 陶黎明. 康柏西普联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿患者远期视力恢复的影响因素研究[J]. 眼科新进展, 2021, 41(2): 174-177.</mixed-citation></ref><ref id="hanspub.44700-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">毛新帮, 赵菊莲, 游志鹏. 视网膜血管阻塞性疾病的治疗进展[J]. 中国实用眼科杂志, 2006, 24(12): 1240-1243.</mixed-citation></ref><ref id="hanspub.44700-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">陶相宜, 郭淑玲, 董微丽. 探讨视网膜激光光凝术治疗各种眼底病的临床疗效[J]. 河北医学, 2017, 23(2): 238-240.</mixed-citation></ref><ref id="hanspub.44700-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">张承芬. 常见眼底病的光凝治疗[M]. 北京: 人民卫生出版社, 1998: 700-713.</mixed-citation></ref><ref id="hanspub.44700-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Early Treatment Diabetic Retinopathy Study Group (1985) Photocogulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study report No.1. Archives of Ophthalmology, 103, 1796-1806</mixed-citation></ref><ref id="hanspub.44700-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">郑波, 王勇, 王丽丽. 激光格栅样光凝治疗视网膜中央静脉阻塞致黄斑囊样水肿的分析[J]. 国际眼科杂志, 2011, 11(6): 1046-1048.</mixed-citation></ref><ref id="hanspub.44700-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">陈少军, 阴正勤, 杨红, 吴楠, 李世迎, 孟晓红. 曲安奈德和激光治疗静脉阻塞性黄斑水肿[J]. 国际眼科杂志, 2012, 12(11): 2154-2156.</mixed-citation></ref><ref id="hanspub.44700-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">岳建中, 夏智渝, 张安民, 杨英. IVR联合激光光凝治疗对视网膜静脉阻塞继发黄斑水肿患者VEGF、CRT、BCVA、眼压的影响[J]. 临床误诊误治, 2019, 32(4): 38-43.</mixed-citation></ref><ref id="hanspub.44700-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">姜燕荣, 王凯, 黎晓新. 曲安奈德玻璃体腔注射治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J]. 眼科研究, 2006, 4(6): 639-642.</mixed-citation></ref><ref id="hanspub.44700-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">马艳波, 王洁, 马秋莎. 曲安奈德治疗视网膜静脉阻塞继发黄斑水肿临床观察[J]. 中外医疗, 2014(22): 131-133.</mixed-citation></ref><ref id="hanspub.44700-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Haller, J.A., Bandello, F., Belfortr Blumenkranz, M.S., Gillies, M., Heier, J., et al. (2011) Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Ophthalmology, 118, 2453-2460. &lt;br&gt;https://doi.org/10.1016/j.ophtha.2011.05.014</mixed-citation></ref><ref id="hanspub.44700-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kuppermann, B.D., Haller, J.A., Bandello, F., Loewen-Stein, A., Jiao, J., Li, X.Y., et al. (2014) Onset and Duration of Visual Acuity Improvement after Dexamethasone Intravitreal Implant in Eyes with Macular Edema Due to Retinal Vein Occlusion. Retina, 34, 1743-1749. &lt;br&gt;https://doi.org/10.1097/IAE.0000000000000167</mixed-citation></ref><ref id="hanspub.44700-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">中国视网膜静脉阻塞地塞米松玻璃体腔植入剂研究组, 黎晓新, 王宁利, 梁小玲, 徐格致, Xiao-yan Li, Jenny Jiao, Jean Lou, Yehia Hashad. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性: 随机、假注射对照、多中心研究[J]. 中华眼底病杂志, 2018, 34(3): 212-220.</mixed-citation></ref><ref id="hanspub.44700-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">谷潇雅, 戴虹, 喻晓兵. 地塞米松玻璃体腔植入剂治疗视网膜静脉阻塞继发黄斑水肿一年临床观察[J]. 中华眼底病杂志, 2018, 34(3): 221-227.</mixed-citation></ref><ref id="hanspub.44700-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Funatsu, H., Harino, S., et al. (2011) Vitreous Inflammatory Factorsin Macular Edema with Central Retinal Vein Occlusion. Japanese Journal of Ophthalmology, 55, 248-255. &lt;br&gt;https://doi.org/10.1007/s10384-011-0016-4</mixed-citation></ref><ref id="hanspub.44700-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Mimura, T., Yasuda, K., et al. (2015) Role of Soluble Vascular Endothelial Growth Factor Receptor Signaling and Other Factors or Cytokines in Central Retinal Vein Occlusion with Macular Edema. Investigative Ophthalmology &amp; Visual Science, 56, 1122-1128. &lt;br&gt;https://doi.org/10.1167/iovs.14-15789</mixed-citation></ref><ref id="hanspub.44700-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ferrara, N., Damico, I., Shams, N., et al. (2006) Development of Ranibizumab. An Anti-Vascular Endothelial Growth Factor Antigen Binding Fragment, as Therapy for Neovascular Age Related Macular Degeneration. Retina, 2.</mixed-citation></ref><ref id="hanspub.44700-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">万珊珊, 杨燕宁, 邢怡桥, 满子惠, 饶卓群. 雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿的效果及安全性的系统评价[J]. 中国医药报, 2013, 10(27): 62-64, 67.</mixed-citation></ref><ref id="hanspub.44700-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">李路明, 杨少华. 雷珠单抗玻璃体内注射治疗视网膜静脉阻塞黄斑水肿[J]. 世界复合医学, 2020, 6(10): 171-173.</mixed-citation></ref><ref id="hanspub.44700-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">沈宵, 常青. 视网膜静脉阻塞抗血管内皮生长因子治疗研究进展[J]. 中华眼底病杂志, 2013, 29(6): 634-637.</mixed-citation></ref><ref id="hanspub.44700-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Epstein, D.L., Algvere, P.V., von Wendt, G., et al. (2012) Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Aprospective, Randomized, Double-Masked Clinical Study. Ophthalmology, 119, 2587-2591.  
&lt;br&gt;https://doi.org/10.1016/j.ophtha.2012.06.037</mixed-citation></ref><ref id="hanspub.44700-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Averyrl, Castellarinaa, Steinlenc, Dhootds, Pieramicidj, Seer, et al. (2017) Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina, 37, 1847-1858.  
&lt;br&gt;https://doi.org/10.1097/IAE.0000000000001493</mixed-citation></ref><ref id="hanspub.44700-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">吴冠男, 张笑天, 何广辉, 董蒙, 高翔, 王梦, 陈松. 阿柏西普治疗视网膜静脉阻塞继发黄斑水肿的视网膜微血管改变及视力预后分析[J]. 中华眼底病杂志, 2021, 37(4): 290-297.</mixed-citation></ref><ref id="hanspub.44700-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Scott, I.U., Oden, N.L., Van Veldhuisen, P.C., et al. (2019) Month 24 Outcomes after Treatment Initiation with Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A secondary Analysis of the SCORE2 Randomized Clinical Trial. JJAMA Ophthalmology, 137, 1389-1398. &lt;br&gt;https://doi.org/10.1001/jamaophthalmol.2019.3947</mixed-citation></ref><ref id="hanspub.44700-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Casselholm de Salles, M., Amrén, U., Kvanta, A., et al. (2019) Injection Frequency of Aflibercept versus Ranibizumab in a Treat-and-Extend Regimen for Central Retinal Vein Occlusion: A Randomized Clinical Trial. Retina, 39, 1370-1376. &lt;br&gt;https://doi.org/10.1097/IAE.0000000000002171</mixed-citation></ref><ref id="hanspub.44700-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">张军军, 张美霞. 湿性年龄相关性黄斑变性治疗方法的新选择[J]. 中华实验眼科杂志, 2012, 30(11): 961-964.</mixed-citation></ref><ref id="hanspub.44700-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">郭超. 康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2019.</mixed-citation></ref><ref id="hanspub.44700-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">赵宏锟, 吴敏. 康柏西普不同给药方案治疗视网膜分支静脉阻塞继发黄斑水肿[J]. 国际眼科杂志, 2019, 19(4): 567-570.</mixed-citation></ref><ref id="hanspub.44700-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Nishida, A., Kojima, H., Kameda, T., Mandai, M. and Kurimo-To, Y. (2017) Five-Year Outcomes of Pars Plana Vitrectomy for Macular Edema Associated with Branch Retinal Vein Occlusion. Clinical Ophthalmology, 11, 369-375.  
&lt;br&gt;https://doi.org/10.2147/OPTH.S123419</mixed-citation></ref><ref id="hanspub.44700-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">张燕. 玻璃体切割联合内界膜剥离治疗RVO继发黄斑水肿[J]. 国际眼科杂志, 2012, 12(8): 1581-1582.</mixed-citation></ref><ref id="hanspub.44700-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">邵毅, 张雨晴, 周琼. 视网膜静脉阻塞诊疗规范——2019年欧洲视网膜专家协会指南解读[J]. 眼科新进展, 2020, 40(6): 501-504.</mixed-citation></ref></ref-list></back></article>